NASDAQ:SPRY

ARS Pharmaceuticals (SPRY) Stock Forecast, Price & News

$6.62

-0.20 (-2.93%)

(As of 06/7/2023 ET)

Compare

Today's Range: $6.62
▼
$7.02
50-Day Range: $4.52
▼
$9.09
52-Week Range: $3.68
▼
$9.65

Volume: 552,500 shs
Average Volume: 4.01 million shs
Market Capitalization: $627.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

ARS Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 106.4% Upside
$13.67 Price Target
Short Interest: Bearish
7.65% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.07
Based on 4 Articles This Week
Insider Trading: Selling Shares
$724,600 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.75) to ($0.82) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

623rd out of 981 stocks

Pharmaceutical Preparations Industry

306th out of 485 stocks

3.5

Analyst's Opinion

Consensus Rating
ARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.67, ARS Pharmaceuticals has a forecasted upside of 106.4% from its current price of $6.62.
Amount of Analyst Coverage
ARS Pharmaceuticals has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.65% of the float of ARS Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
ARS Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
ARS Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ARS Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SPRY.

2.2

News and Social Media Coverage

News Sentiment
ARS Pharmaceuticals has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for ARS Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
10 people have searched for SPRY on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
3 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $724,600.00 in company stock.
Percentage Held by Insiders
34.40% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for ARS Pharmaceuticals are expected to decrease in the coming year, from ($0.75) to ($0.82) per share.
Price to Book Value per Share Ratio
ARS Pharmaceuticals has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ARS Pharmaceuticals (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Receive SPRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPRY Stock News Headlines

June 5, 2023 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $496,801.20 in Stock

June 2, 2023 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 4.8%

June 8, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

May 23, 2023 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) to Post Q2 2023 Earnings of ($0.19) Per Share, Wedbush Forecasts

May 20, 2023 | americanbankingnews.com

Q2 2023 Earnings Forecast for ARS Pharmaceuticals, Inc. Issued By SVB Leerink (NASDAQ:SPRY)

May 20, 2023 | americanbankingnews.com

ARS Pharmaceuticals, Inc. Forecasted to Post Q2 2023 Earnings of ($0.22) Per Share (NASDAQ:SPRY)

May 18, 2023 | markets.businessinsider.com

Wedbush Keeps Their Buy Rating on ARS Pharmaceuticals (SPRY)

May 15, 2023 | finance.yahoo.com

ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray

June 8, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

May 15, 2023 | msn.com

ARS Pharmaceuticals: Potential Revolution In Allergy Treatment With Neffy

May 15, 2023 | finance.yahoo.com

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

May 12, 2023 | wsj.com

ARS Pharmaceuticals Inc.

May 12, 2023 | markets.businessinsider.com

FDA Panel Votes In Favor Of ARS Pharma's Neffy For Allergic Reactions Treatment

May 12, 2023 | markets.businessinsider.com

Why ARS Pharmaceuticals Stock Is Soaring Today

May 12, 2023 | marketwatch.com

ARS Pharmaceuticals Soar 68% in Premarket Trading as FDA Panel Backs Neffy >SPRY

May 12, 2023 | americanbankingnews.com

Laura Shawver Sells 42,900 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

May 12, 2023 | seekingalpha.com

FDA advisors endorse benefits of ARS Pharma epinephrine nasal spray

May 11, 2023 | finance.yahoo.com

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

May 10, 2023 | businesswire.com

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

May 9, 2023 | benzinga.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

May 9, 2023 | msn.com

ARS Pharma down 12% on FDA AdCom docs for epinephrine nasal spray

May 9, 2023 | markets.businessinsider.com

FDA Issues Some Concerns Regarding ARS Pharma's Investigational Allergy Treatment

May 9, 2023 | finance.yahoo.com

ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis

April 28, 2023 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) to Post Q1 2023 Earnings of ($0.13) Per Share, SVB Leerink Forecasts

April 26, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Veru (VERU) and ARS Pharmaceuticals (SPRY)

April 25, 2023 | markets.businessinsider.com

SVB Securities Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

April 21, 2023 | finance.yahoo.com

Companies Like ARS Pharmaceuticals (NASDAQ:SPRY) Are In A Position To Invest In Growth

See More Headlines

SPRY Price History

30 days | 90 days | 365 days | Advanced Chart

SPRY Company Calendar

Last Earnings: 5/15/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SPRY
CUSIP: N/A
CIK: 1671858
Web: ars-pharma.com
Phone: 206-456-2900
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.67
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +106.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,680,000.00
Net Margins: N/A
Pretax Margin: -6,299.11%
Return on Equity: -15.70%
Return on Assets: -15.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 27.17
Quick Ratio: 27.18

Sales & Book Value

Annual Sales: $1.32 million
Price / Sales: 475.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.90 per share
Price / Book: 2.28

Miscellaneous

Outstanding Shares: 94,770,000
Free Float: 62,172,000
Market Cap: $627.38 million
Optionable: Optionable
Beta: -0.17

Key Executives

Mr. Richard Lowenthal M.B.A. (Age 56)
M.S., MSMSEL, Founder, Pres, CEO & Director

Dr. Sarina Tanimoto M.B.A. (Age 54)
M.D., Co-Founder & Chief Medical Officer

Dr. Robert Bell Ph.D.
Co-Founder & Chief Science Officer

Ms. Kathleen D. Scott CPA
Chief Financial Officer

Mr. Brian T. Dorsey M.S.
SVP of Operations & Project Management

Mr. Daniel Relovsky
Sr. VP of Marketing

Mr. Harris Kaplan M.B.A. (Age 70)
MBA, Exec. VP of Commercial Strategy

Mr. Eric Karas (Age 50)
Chief Commercial Officer

Mr. Justin Chakma (Age 33)
Chief Bus. Officer & Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SPRY Stock - Frequently Asked Questions

Should I buy or sell ARS Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRY shares.
View SPRY analyst ratings or view top-rated stocks.
What is ARS Pharmaceuticals' stock price forecast for 2023?: 3 brokerages have issued 12-month price targets for ARS Pharmaceuticals' stock. Their SPRY share price forecasts range from $10.00 to $17.00. On average, they predict the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 106.4% from the stock's current price.
View analysts price targets for SPRY or view top-rated stocks among Wall Street analysts.
How have SPRY shares performed in 2023?: ARS Pharmaceuticals' stock was trading at $8.53 at the beginning of 2023. Since then, SPRY stock has decreased by 22.4% and is now trading at $6.62.
View the best growth stocks for 2023 here.
When is ARS Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SPRY earnings forecast.
How were ARS Pharmaceuticals' earnings last quarter?: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The company had revenue of $0.02 million for the quarter.
What ETFs hold ARS Pharmaceuticals' stock?: ETFs with the largest weight of ARS Pharmaceuticals (NASDAQ:SPRY) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), IQ Chaikin U.S. Small Cap ETF (CSML), Invesco DWA SmallCap Momentum ETF (DWAS), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB),

What is ARS Pharmaceuticals' stock symbol?: ARS Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPRY."
Who are ARS Pharmaceuticals' major shareholders?: ARS Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include SR One Capital Management LP (4.23%), Baker BROS. Advisors LP (2.12%), Geode Capital Management LLC (0.43%), Royce & Associates LP (0.32%), Ameriprise Financial Inc. (0.30%) and Jane Street Group LLC (0.15%). Insiders that own company stock include Kathleen D Scott and Laura Shawver.
View institutional ownership trends.
How do I buy shares of ARS Pharmaceuticals?: Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ARS Pharmaceuticals' stock price today?: One share of SPRY stock can currently be purchased for approximately $6.62.
How much money does ARS Pharmaceuticals make?: ARS Pharmaceuticals (NASDAQ:SPRY) has a market capitalization of $627.38 million and generates $1.32 million in revenue each year.
How can I contact ARS Pharmaceuticals?: ARS Pharmaceuticals' mailing address is 500 Fairview Ave N Suite 600, Seattle WA, 98109. The official website for the company is ars-pharma.com. The company can be reached via phone at 206-456-2900 or via email at ir@silverbacktx.com.

This page (NASDAQ:SPRY) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial